WARSAW, Ind., Aug. 17, 2021 /PRNewswire/ -- Zimmer Biomet
Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology
leader, today announced six data presentations at the American
Academy of Orthopaedic Surgeons (AAOS) 2021 Annual Meeting
scheduled to be held on August 31 to
September 3 in San Diego.
The accepted data include a podium presentation showcasing
Persona IQ®, the Company's
investigational smart knee implant developed in partnership with
Canary Medical and currently under review by the FDA, and three
posters on the clinical utility and value of Zimmer Biomet's remote
care management platform, mymobility® with Apple
Watch®.
"We are excited to share new data and showcase the newest
additions to our innovative and comprehensive portfolio of products
and technologies designed to restore mobility and transform the
patient experience," said Ivan Tornos, Chief Operating Officer of
Zimmer Biomet. "This year, we're proud to preview our
investigational smart knee implant, alongside ROSA Hip, which is
currently under review by the FDA for robotically-assisted anterior
hip replacement. ROSA Hip and Persona IQ, once cleared, will be
featured as a part of our ZBEdge Connected Intelligence suite of
integrated digital and robotic technologies."
Following are the details of the scheduled data presentations at
AAOS 2021:
Podium Sessions
- Paper 458 - A Smartwatch Paired Mobile Application
Provides Postoperative Self-Directed Rehabilitation Without
Compromising Patient Outcomes: A Randomized Controlled
Trial
Lead Presenter: Krishna
Tripuraneni, MD, FAAOS
Session: Adult Reconstruction Knee IV
September 2, 2021
8:50AM – 8:55AM PT
Ballroom 6A
- Paper 459 - The Talking Knee is a Reality: Remote Patient
Monitoring Prosthesis for Total Knee Arthroplasty
Lead
Presenter: Fred D. Cushner, MD,
FAAOS, Hospital for Special Surgery
Session: Adult Reconstruction Knee IV
September 2, 2021
9:00AM – 9:05AM PT
Ballroom 6A
- Paper 509 - 7-Year Radiographic and Clinical Follow-Up of
Vitamin E-Diffused Polyethylene Liners in Total Hip Arthroplasty:
Findings from a Prospective, International, Multicenter Study of
977 Patients
Lead Presenter: Charles
R. Bragdon, PhD, Mass General Hospital
Session: Adult Reconstruction Hip V
September 2, 2021
11:20AM – 11:25AM PT
Ballroom 6B
Poster Presentations - September
2, 2021, 7:00AM –
5:00PM PT (Academy Hall – Sails
Pavilion)
- P0542 - The Recovery Curve for Physical Activity Following
Primary Total Hip Arthroplasty Using Average Daily Step Counts
Measured with a Smartphone-based Care Platform and Smart
Watch
- P0528 - The Relationship of Common Patient Reported Outcomes
and Passively Collected Outcome Measures in Adult
Reconstruction
- P0765 - Use of a Smartphone-based Care Platform After
Primary Joint Arthroplasty: A Prospective Randomized Trial
Full abstracts of the planned presentations will be available on
the AAOS website on August 31, 2021,
at https://www.aaos.org/annual/education/browse-education/.
Exhibit Booth Information
Zimmer Biomet is planning to showcase its latest integrated
digital and robotic technologies at Booth #2535. Click HERE to
visit the Company's virtual exhibit booth which will go live on
August 31, 2021.
About the Company
Zimmer Biomet is a global medical technology leader with a
comprehensive portfolio designed to maximize mobility and improve
health. We seamlessly transform the patient experience through our
innovative products and suite of integrated digital and robotic
technologies that leverage data, data analytics and artificial
intelligence.
With 90+ years of trusted leadership and proven expertise,
Zimmer Biomet is positioned to deliver the highest quality
solutions to patients and providers. Our legacy continues to come
to life today through our progressive culture of evolution and
innovation.
For more information about our product portfolio, our operations
in 25+ countries and sales in 100+ countries or about joining our
team, visit www.zimmerbiomet.com or follow Zimmer Biomet on Twitter
at www.twitter.com/zimmerbiomet.
Cautionary Statement Regarding Forward-Looking
Statements
This news release contains forward-looking
statements within the meaning of the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995.
Forward-looking statements include, but are not limited to,
statements concerning Zimmer Biomet's expectations, plans,
prospects, and product and service offerings, including new product
launches and potential clinical successes. Such statements
are based upon the current beliefs and expectations of management
and are subject to significant risks, uncertainties and changes in
circumstances that could cause actual outcomes and results to
differ materially. For a list and description of some of such
risks and uncertainties, see Zimmer Biomet's periodic reports filed
with the U.S. Securities and Exchange Commission
(SEC). These factors should not be construed as exhaustive
and should be read in conjunction with the other cautionary
statements that are included in Zimmer Biomet's filings with the
SEC. Forward-looking statements speak only as of the date
they are made, and Zimmer Biomet disclaims any intention or
obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or
otherwise. Readers of this news release are cautioned not to
rely on these forward-looking statements, since there can be no
assurance that these forward-looking statements will prove to be
accurate. This cautionary statement is applicable to all
forward-looking statements contained in this news release.
Apple Watch® is a registered trademark of Apple, Inc.
ZBH-Corp
Contacts:
|
|
|
|
Media
|
|
Meredith
Weissman
|
|
(703)
346-3127
|
|
meredith.weissman@zimmerbiomet.com
|
|
|
|
Investors
|
|
Ezgi
Yagci
|
Keri
Mattox
|
(617)
549-2443
|
(203)
399-0856
|
ezgi.yagci@zimmerbiomet.com
|
keri.mattox@zimmerbiomet.com
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/zimmer-biomet-to-unveil-new-clinical-data-and-portfolio-of-innovative-technologies-at-aaos-2021-annual-meeting-301356280.html
SOURCE Zimmer Biomet Holdings, Inc.